Nevertheless, the FDA recently approved a dopamine transporter (DAT) single-photon emission computerized tomography (SPECT) to evaluate suspicions of Parkinson’s disease, which can be seen as evidence of the next imaging-based diagnostic in AD [46]. This evidence concerns the gene SLC6A3 and Alzheimer disease.